+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dementia Drugs Market - Global Forecast 2026-2032- Product Image
Dementia Drugs Market - Global Forecast 2026-2032- Product Image
New

Dementia Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083640
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The dementia drugs market is rapidly evolving, fueled by scientific innovation, regulatory shifts, and emerging commercial models. Senior decision-makers need precise, actionable intelligence to align clinical strategies, market access, and operational responses in a dynamic therapeutic landscape.

Market Snapshot

The Dementia Drugs Market is experiencing strong growth, increasing from USD 11.96 billion in 2025 to USD 13.28 billion in 2026. Projected to advance at a CAGR of 11.96%, the sector is set to reach USD 26.39 billion by 2032. This expansion reflects not just demographic trends, but also advances in diagnosis, therapy differentiation, and the restructuring of commercial and distribution channels.

Dementia Drugs Market Scope & Segmentation

This report delivers comprehensive coverage of the dementia therapeutics market across all key forces, segmented to support effective strategic positioning and resource allocation.

  • Therapeutic Classes: Including cholinesterase inhibitors (donepezil, galantamine, rivastigmine), NMDA receptor antagonists (memantine), and combination therapies, each with distinctive clinical profiles and prescriber dynamics.
  • Distribution Channels: Hospital, retail, specialty, and online pharmacies, each channel influencing patient access, support programs, and distribution strategies.
  • End-User Settings: Clinics, hospitals, long-term care facilities, and home care, impacting adherence, monitoring, and caregiver engagement models.
  • Treatment Approaches: Monotherapies and combination therapies requiring tailored value narratives.
  • Administration Routes: Oral and transdermal formats, affecting adherence, tolerability, and product logistics.
  • Patient Demographics: Analysis by age cohort and disease stage, considering comorbidities and unique care challenges.
  • Patent Status: Branded versus generic products shaping pricing, contracting, and investment decisions.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific, each featuring distinct regulatory frameworks, payer models, and supply chain influences.

Dementia Drugs Market: Key Takeaways

  • Scientific advancements, notably biomarker-driven diagnostics and updated endpoints, are prompting more segment-specific therapies and creating new expectations among all stakeholders.
  • Manufacturers are reshaping portfolios and partnership models to address both established symptomatic therapies and pipeline innovations, seeking life-cycle management advantages and value-based evidence.
  • Channel strategy is increasingly pivotal, with digital distribution, specialty pharmacy, and expanded home care solutions redefining access and adherence interventions across varied care settings.
  • Evolving regulatory environments now accommodate novel modalities and endpoints, requiring adaptive engagement for reimbursement, formulary inclusion, and healthcare policy navigation.
  • Market segmentation and competitive pressure, especially from generic entry and combination therapies, necessitate agile communication of clinical and economic value to diverse payer and provider groups.

Tariff Impact on the Dementia Drugs Market

New United States tariff policies introduced in 2025 are reshaping manufacturing and distribution strategies for dementia therapeutics. These tariffs are driving manufacturers to adjust supply chains, repatriate production, renegotiate supplier agreements, and reassess distribution models to mitigate margin pressure and ensure supply continuity. Downstream, increased input costs prompt procurement teams to prioritize budget efficiency, reevaluate sourcing, and adopt alternative reimbursement and contracting strategies. Vertically integrated approaches, robust scenario planning, and increased commercial-supply chain collaboration are emerging as critical responses to tariff-induced market pressures.

Methodology & Data Sources

This analysis combines clinical evidence reviews, regulatory documentation, qualitative interviews with clinicians and supply chain leaders, and scenario modeling. Data triangulation ensures robust, theme-driven findings across therapeutic classes, channels, and regions, supporting strategic planning and operational resilience. Limitations and variable regional data are transparently documented to ensure localized applicability.

Why This Report Matters

  • Supports strategic decisions by linking clinical evidence, operational tactics, and commercial opportunities.
  • Enables adaptive planning amid evolving regulatory, competitive, and policy environments.
  • Equips executive leaders to anticipate access challenges and harness opportunities for sustainable market impact.

Conclusion

As science, care models, and policy converge, integrated strategies aligning innovation, supply resilience, and market access are now essential for leadership in dementia therapeutics. Applying these insights will help organizations convert disruption into sustainable value and enhanced patient outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Dementia Drugs Market, by Drug Class
8.1. Cholinesterase Inhibitors
8.1.1. Donepezil
8.1.2. Galantamine
8.1.3. Rivastigmine
9. Dementia Drugs Market, by Treatment Type
9.1. Combination Therapy
9.2. Monotherapy
10. Dementia Drugs Market, by Route Of Administration
10.1. Oral
10.2. Transdermal
11. Dementia Drugs Market, by Patient Age Group
11.1. 65 To 74
11.2. 75 To 84
11.3. 85 And Above
11.4. Under 65
12. Dementia Drugs Market, by Disease Stage
12.1. Mild
12.2. Moderate
12.3. Severe
13. Dementia Drugs Market, by Patent Status
13.1. Branded
13.2. Generic
14. Dementia Drugs Market, by Distribution Channel
14.1. Hospital Pharmacy
14.2. Online Pharmacy
14.3. Retail Pharmacy
14.4. Specialty Pharmacy
15. Dementia Drugs Market, by End User
15.1. Clinics
15.2. Home Care Settings
15.3. Hospitals
15.4. Long-Term Care Facilities
16. Dementia Drugs Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Dementia Drugs Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Dementia Drugs Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Dementia Drugs Market
20. China Dementia Drugs Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. AC Immune SA
21.6. AstraZeneca plc
21.7. Axsome Therapeutics, Inc.
21.8. Cassava Sciences, Inc.
21.9. Eisai Co., Ltd.
21.10. Eli Lilly and Company
21.11. F. Hoffmann-La Roche Ltd.
21.12. H. Lundbeck A/S
21.13. Johnson & Johnson
21.14. Merck & Co., Inc.
21.15. Novartis AG
21.16. Otsuka Pharmaceutical Co., Ltd.
List of Figures
FIGURE 1. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. EUROPE DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 129. EUROPE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 131. EUROPE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. EUROPE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 153. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 154. AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 155. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASEAN DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 170. ASEAN DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 172. ASEAN DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. ASEAN DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 174. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 175. ASEAN DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 176. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. ASEAN DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. GCC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. GCC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 180. GCC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 181. GCC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 182. GCC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. GCC DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. GCC DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 185. GCC DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 186. GCC DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. GCC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. BRICS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. BRICS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. BRICS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. BRICS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 202. BRICS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. BRICS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 204. BRICS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 205. BRICS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 206. BRICS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. BRICS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. G7 DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. G7 DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. G7 DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 211. G7 DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 212. G7 DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. G7 DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 214. G7 DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 215. G7 DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 216. G7 DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. G7 DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. NATO DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. NATO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 220. NATO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 221. NATO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 222. NATO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. NATO DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 224. NATO DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 225. NATO DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 226. NATO DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 227. NATO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. CHINA DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 241. CHINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 242. CHINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 243. CHINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 245. CHINA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 246. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
TABLE 247. CHINA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 248. CHINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Dementia Drugs market report include:
  • AC Immune SA
  • AstraZeneca plc
  • Axsome Therapeutics, Inc.
  • Cassava Sciences, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.28 Billion
Forecasted Market Value ( USD ) by 2032 $ 26.39 Billion
Compound Annual Growth Rate11.9%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Anti-dementia Drugs Market - Global Forecast 2025-2030 - Product Image

Anti-dementia Drugs Market - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Lewy Body Dementia Treatment Market - Global Forecast 2026-2032 - Product Image

Lewy Body Dementia Treatment Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Dementia Drugs Market Report and Forecast 2025-2034 - Product Image

Dementia Drugs Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Dementia Treatment Market Report 2025 - Product Image

Dementia Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Lewy Body Dementia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Lewy Body Dementia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Dementia Drug Market

The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators. Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.